Fulgent Genetics Partners with Parkinson’s Foundation on Launch of Genetic Testing Initiative for People with Parkinson’s...
July 16 2019 - 9:15AM
Fulgent Genetics (NASDAQ: FLGT) and the Parkinson’s Foundation
today announced a collaboration on a new genetic testing initiative
for individuals living with Parkinson’s Disease (PD). The
nation-wide initiative, called PD GENEration: Mapping the Future of
Parkinson’s Disease, provides genetic testing for clinically
relevant Parkinson’s-related genes for eligible individuals. The
initiative will be offered through the Parkinson’s Foundation
Centers of Excellence network and Parkinson Study Group sites, and
it will leverage the next generation genetic testing technology of
Fulgent Genetics.
“Fulgent is proud to be partnering with the Parkinson’s
Foundation on such an important initiative, and we were pleased to
be chosen as their genetic testing partner following a competitive
selection process, offering the best overall value and solution for
the Foundation,” said Ming Hsieh, Chairman and CEO of Fulgent
Genetics. “Our comprehensive testing and data analytics
capabilities will enable clinicians to make more informed treatment
decisions for Parkinson’s patients, which we believe will have a
positive impact on patient care. We also look forward to leveraging
our data and technology capabilities to aid in the development of
improved treatments for Parkinson’s patients in the future.”
Fulgent Genetics is uniquely positioned to support PD GENEration
given the company’s history of implementing state-of-the-art next
generation sequencing technology to advance the field of genetic
testing. As part of the collaboration agreement, Fulgent Genetics
will be compensated for processing, sequencing, and storing each
DNA sample for patients participating in the initiative. Also
supporting this initiative are Indiana University School of
Medicine, providing genetic counseling for tested individuals;
University of Florida CTSI Data Coordinating Center, assisting with
secure data storage; and University of Rochester’s Clinical Trials
Coordination Center. In collaboration with these partners, Fulgent
Genetics has leveraged the flexibility of its broad testing catalog
to select and develop a targeted list of seven genes relevant to
Parkinson’s patients and clinicians: GBA, LRRK2, SNCA, PRKN, PARK7,
VPS35, and PINK1. Fulgent Genetics will analyze and generate
clinical reports for these target genes, and the findings will be
made available to the treating physicians and future
researchers.
Genetic testing can help determine whether an individual’s
genetic makeup indicates a potential genetic cause for Parkinson’s
disease. This knowledge can assist patients and physicians in
better understanding each case and can help to identify whether a
patient qualifies for enrollment in certain clinical trials.
Participants will also be able to better understand their genetic
test results through free genetic counseling provided by Indiana
University and on-site clinicians. Raw data accumulated through the
initiative will be captured for future research by scientists to
develop improved treatments and precision medicine options for
PD.
The initiative aims to enroll 600 participants in its first year
of operation, expanding to include 15,000 participants by 2024.
“What makes PD GENEration unique is its novel approach of
offering genetic testing for relevant Parkinson’s-related genes in
an easily accessible, clinical environment through the Parkinson’s
Foundation network,” said James Beck, PhD, Chief Scientific Officer
at the Parkinson’s Foundation. “We expect that this will accelerate
enrollment in clinical trials for the next generation of treatments
and help facilitate the use of genetic information to improve care
and expand research.”
To learn more about Fulgent Genetics, visit
FulgentGenetics.com.To learn more about the PD GENEration
initiative, call 1-800-4PD-INFO or visit
www.Parkinson.org/PDGENEration.
About Fulgent GeneticsFulgent Genetics (NASDAQ:
FLGT) is a technology company with a focus on offering
comprehensive genetic testing to provide physicians with clinically
actionable diagnostic information they can use to improve the
quality of patient care. The company has developed a proprietary
technology platform that allows it to offer a broad and flexible
test menu and continually expand and improve its proprietary
genetic reference library, while maintaining accessible pricing,
high accuracy and competitive turnaround times. The company
believes its test menu, which currently offers more genes for
testing than its competitors in today’s market, enables it to
provide expansive options for test customization and clinically
actionable results.
Investor Relations Contact:The Blueshirt GroupNicole Borsje,
415-217-2633, nborsje@blueshirtgroup.com
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart
From Sep 2023 to Sep 2024